Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.46 |
| ▸ | CCR5 | P51681 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7801189 | 0.94 | ENPP2 (0.55) | ENPP2PTGDR2CCR5SIGMAR1CHRM2 | |
| SCHEMBL190556 | 0.93 | ENPP2 (0.57) | ENPP2PTGDR2CCR5SIGMAR1ALDH1A1 | |
| SCHEMBL22285161 | 0.93 | ENPP2 (0.57) | ENPP2PTGDR2CCR5SIGMAR1ALDH1A1 | |
| SCHEMBL4785540 | 0.90 | ALDH1A1 (0.50) | ENPP2PTGDR2CCR5SIGMAR1CHRM2 | |
| SCHEMBL4964527 | 0.89 | CCR5 (0.47) | ENPP2PTGDR2CCR5SIGMAR1CHRM2 | |
| SCHEMBL1162705 | 0.88 | ENPP2 (0.42) | ENPP2PTGDR2CCR5SIGMAR1CHRM2 | |
| SCHEMBL13434086 | 0.85 | CCR5 (0.59) | CCR5SIGMAR1ALDH1A1L3MBTL1 | |
| SCHEMBL28523905 | 0.85 | ENPP2 (0.51) | ENPP2PTGDR2CCR5SIGMAR1CHRM2 | |
| SCHEMBL14975918 | 0.85 | CCR5 (0.46) | ENPP2PTGDR2CCR5SIGMAR1CHRM2 | |
| SCHEMBL32691106 | 0.84 | CCR6 (0.46) | ENPP2PTGDR2CCR5SIGMAR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| CN-114729006-A | Cyclic peptide compounds having Kras inhibitory activity | 中外制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| EP-1134219-B1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6573260-B1 | Antibiotics | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1134219-A1 | CYCLOALKYL-SUBSTITUTED AMINOMETHYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-4250085-A | PHOSPHONATE-CONTAINING OLIGOPEPTIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-02-10 | — | — | US | disclosed |
| EP-0002822-A1 | Phosphorus containing peptide derivatives, their production, intermediates for their production and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ENPP2 1461/4885PTGDR2 3740/4885CCR5 1349/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ENPP2 1461/4885PTGDR2 3740/4885CCR5 1349/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | ENPP2 1461/4885PTGDR2 3740/4885CCR5 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.